UBS keeps EUR 260 target for Sartorius Stedim stock

Published on 10/16/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock costs EUR 218.70 on October 16, 2026, 2.80 percent below its EUR 225.00 high. Results follow October 22.

Analyst targets and reporting date

UBS kept its EUR 260.00 target and Buy rating on October 14, 2026.
Fiscal year 2026 guidance calls for 6 to 10 percent sales growth and an underlying EBITDA margin above 31 percent.
Sartorius Stedim stock trades at EUR 218.70 at 10:16 a.m. CEST at Lang & Schwarz on October 16, 2026.
Third-quarter results are scheduled for October 22, 2026.

Flatlay mit Laborpipetten, Filtermembranen, Schutzhandschuhen und ISIN-Karte FR0013154002 — Sartorius Stedim Biotech Flatlay mit Laborpipetten, Filtermembranen, Aktien-Zertifikat und ISIN-Karte, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim (ISIN FR0013154002) was trading at EUR 218.70 at Lang & Schwarz on October 16, 2026, at 10:16 a.m. CEST, 2.80 percent below its EUR 225.00 52-week high. UBS kept its Buy rating and EUR 260.00 price target in a study dated October 14, 2026, ahead of the company's quarterly results, according to Aktiencheck.

UBS keeps growth at the center

UBS linked its positive stance to the underlying growth path of Sartorius Stedim, while highlighting tariffs as a factor that investors must include in their assessment. The EUR 260.00 target stands EUR 41.30 above the Lang & Schwarz price, giving the analyst view a concrete valuation reference.

A separate analysis from AlphaValue/Baader Europe raised its price target to EUR 253.00 while cutting its earnings-per-share forecasts for 2026 and 2027 by 9.20 percent and 7.96 percent, respectively. Finimize reported that the changes reflected higher depreciation and amortization assumptions, while the firm still expected wider margins from 2027.

What does the October 22 report test?

The next report will test whether the expected recovery is reaching quarterly revenue. Estimates collected by finanzen.ch put third-quarter revenue at EUR 755.60 million, 7.07 percent above the prior-year quarter, and earnings per share at EUR 1.19, 80.30 percent above EUR 0.66. The estimates cover the quarter ended September 30, 2026.

Upcoming reporting date

Sartorius Stedim's investor-relations page schedules the conference call for its nine-month 2026 results on October 22, 2026, at 1:00 p.m. CEST, according to Sartorius Stedim Biotech. The same page gives fiscal year 2026 guidance of 6 to 10 percent sales growth in constant currencies and an underlying EBITDA margin slightly above 31 percent.

Stock stays below the yearly high

The EUR 225.00 52-week high leaves the stock 2.80 percent above its Lang & Schwarz price. The valuation debate therefore combines a near-term reporting date with a longer-term question about consumables-led growth, margin expansion and cash generation.

The stock was trading at EUR 218.70 at Lang & Schwarz on October 16, 2026, at 10:16 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.